International plasma
protein congress (IPPC)

TIME (GMT+1)
‍
09:00 - 09:05
Board Remarks

09:05 - 09:15
Welcome & Opening Ceremony

09:15 - 10:00
Keynote Speech

10:00 - 10:45
Session 1: Resilient and Secure Critical Medicines Supply Chains in the EU – Aspirations and the Reality
Six years after COVID-19, four years after the outbreak of war in Europe, and one year into a major shift in free-trade and globalisation paradigms, where does the EU stand today on supply-chain resilience for critical medicines? What has been improved? Where are the bottlenecks? Which EU and Member State initiatives are currently the main drivers of greater resilience and security of medicine supply chains? Which could deliver a measurable impact for PDMPs?

To what extent are EU and national measures synchronised with industry realities and needs? Where are the key gaps, unintended consequences, or administrative burdens that still hinder resilience? What about global responsibilities of more localised supply chains for critical medicines? This session attempts to answer these pressing questions.

10:45 - 11:30
Networking Break

11:30 - 12:45
Session 2: Challenges and Future Solutions for Anti-D Immunoglobulins in Europe
Medical experts, industry representatives, and other stakeholders will share perspectives on current barriers and emerging opportunities in anti-D plasma collection across Europe, while situating these issues within the broader global landscape. The session will provide an overview of current European practices, highlight cross-border differences, and offer practical considerations for navigating this complex and rapidly changing environment.

12:45 - 14:00
Networking Lunch
‍
14:00 - 15:15
Session 3: From Legislation to Practice: EU Regulatory Reforms and Industry Competitiveness
The EU pharmaceutical and biotech sectors are undergoing significant regulatory change driven by a number of legislative changes, including the EU Pharmaceutical Legislation, the Biotech Act, and environmental initiatives. Together, these reforms are reshaping regulatory processes across the medicines lifecycle management. As the EU seeks to strengthen innovation and competitiveness, regulatory authorities will play a central role in ensuring that new frameworks when implemented are practical, predictable, and innovation-friendly.

This session will examine how EU regulatory evolution will affect the competitiveness of the pharmaceutical and biotech sectors, focusing on authorisation pathways, scientific and procedural requirements, lifecycle management, and the interaction between centralised and decentralised procedures as well as the implications for plasma-derived medicinal industry.

15:15 - 16:00
Networking Break
‍
16:00 - 17:15
Session 4: Strengthening Access to PDMPs Across Europe - Challenges and Opportunities (Market Access)
This panel will explore the major challenges to patient access to plasma-derived medicinal products (PDMPs), from cost-containment and reimbursement  to most-favored-nation policy, stockpiling obligations, supply chain fragility, and patient-centered access measures. Speakers will share perspectives on strategies and frameworks to reinforce the fragile supply chains of PDMPs and ensure sustainable, equitable access for patients across Europe and beyond.
‍
17:15 - 17:30
End of Day / Presentation of the Hilfenhaus Award

17:30 - 19:30
Networking Reception

TIME (GMT+1)

08:30 - 08:35
Board Remarks
‍
08:35 - 08:45
Day 2 Kickoff and Welcome

08:45 - 09:30
Keynote Speech

09:30 - 10:30
Session 5: The Next Generation of Plasma Leadership
The plasma industry and global plasma community are rapidly evolving. Meet expert industry professionals who have advanced in their careers and are poised to assume key leadership roles within their organizations over the next decade. Discover how these informed leaders envision the future of the industry, how innovation within the patient community will shape industry engagement, and the leadership lessons they are carrying forward.
‍
10:30 - 11:30
Session 6: Innovation: From Plasma to PDMPs
Explore the latest innovations in research and development of plasma-derived medicines. The session will highlight the industry's ongoing efforts in developing new therapies, identifying new indications, and translating scientific progress into patient benefit.

11:30 - 12:00
Networking Break

12:00 - 13:00
Session 7: Plasma Donor Health and Safety - A Look Ahead
The first step in building a patient-centric plasma ecosystem is collecting plasma from healthy human donors. This session will feature speakers highlighting current and future research that strengthens donor well-being to ensure a global plasma supply. This discussion will examine emerging scientific insights that responsibly balance innovation, donor protection, and patient needs.

13:00 - 14:15
Networking Lunch

14:15 - 15:15
Session 8 (Plasma Collection in Europe: How to Secure Europe's Future)
Explore how different plasma collection ecosystems contribute to resilience, access, and responsibility in Europe. The session brings together different stakeholders from public and private models to discuss the value and the limits of Europe’s diverse plasma collection ecosystems, in light of the SoHO Regulation, ongoing dependence from the United States and a shifting geopolitical landscape.

15:15-15:30
Closure of IPPC 2026
‍